Objective-CXCL16 and osteoprotegerin (OPG) both predict mortality in acute coronary syndromes. We hypothesized that a combination of CXCL16 and OPG concentrations would add prognostic information to the Global Registry of Acute Coronary Events (GRACE) score in patients hospitalized for acute coronary syndromes. Methods and Results-We assessed the associations between circulating OPG and soluble CXCL16 levels, obtained within 24 hours of admission (day 1) and after 3 months, and mortality, heart failure and reinfarction in 1322 patients admitted with acute coronary syndromes. After adjustment for the GRACE score, medication, diabetes mellitus and sex, the combination of high values (fourth quartile) for OPG and CXCL16 at baseline was associated with increased short-term (3 months) cardiovascular mortality (hazard ratio, 3.28; 95% CI, 1.84-5.82; P<0.0001). The combined high values were also significantly associated with the long-term (median 91 months) prognosis after adjustment, with hazard ratios 2.18 for cardiovascular mortality (95% CI, 1.62-2.92; P<0.0001), and 2.22 for heart failure (95% CI, 1.67-2.96; P<0.0001). These long-term associations remained significant after further adjustment for left ventricular ejection fraction, C-reactive protein, and pro B-type natriuretic peptide. For 635 patients with blood samples within 24 hours and at 3 months, the combination of high CXCL16 and OPG values (fourth quartile) in the early or stable phase was of a similar order associated with mortality and morbidity beyond 3 months. Conclusion-Circulating CXCL16 and OPG are independent predictors of long-term mortality and heart failure development in acute coronary syndromes patients, even after extensive adjustments. Their combination gives more information than either marker alone. (Arterioscler Thromb Vasc Biol. 2012;32:3041-3049.)
T he future of patients experiencing an acute coronary syndrome (ACS) varies considerably, and the identification of those with poor prospects may help in optimizing therapy with outcome benefits. Several strategies for assessing the prognosis in ACS patients have been suggested. 1, 2 For clinical risk stratification, the Global Registry of Acute Coronary Events (GRACE) score is widely used and has been found to provide even better discrimination than the Thrombolysis In Myocardial Infarction (TIMI) score in unstable angina/non-ST-elevation myocardial infarction (MI) patients. 3, 4 Moreover, in line with the pathophysiology behind atherosclerosis, several markers of inflammation have been studied, in most detail C-reactive protein (CRP). 5, 6 We have recently demonstrated that osteoprotegerin (OPG) and CXCL16 predict the long-term prognosis, as well as heart failure (HF), in ACS patients, whereas CXCL16 also predicts recurrent MI. 7, 8 OPG is a soluble decoy receptor in the tumor necrosis factor receptor superfamily, thought to reflect the activity in the OPG/receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand system. This system has been implicated in vascular calcification, 9, 10 the progression of HF, 10 aortic aneurysm development, 11 and the progression of atherosclerosis and plaque destabilization. 9 OPG is upregulated by various inflammatory cytokines, such as tumor necrosis factor α, 11, 12 and it has been suggested that circulating OPG levels may reflect several interacting processes in relation to atherogenesis, remodeling, and inflammation. 13 CXCL16, on the other hand, is upregulated in macrophages by atherogenic lipids 14 and is implicated in the transition of macrophages into foam cells, 15 but it also stimulates smooth muscle cell proliferation and cellcell adhesion. 16 In its membrane-bound form, CXCL16 is a scavenger receptor for oxidized low-density lipoprotein. The proteolytic cleavage of membrane-bound CXCL16 releases soluble CXCL16, which may promote the migration of effector T cells and augment a proatherogenic inflammatory response. Moreover, given the link between inflammatory mediators (ie, interleukin-1β, tumor necrosis factor α and interferon γ) and the cleavage of the membrane-bound CXCL16 to the soluble form of CXCL16, it has been suggested that soluble CXCL16 could serve as a reliable and stable marker of these inflammatory pathways.
Based on the ability of OPG and CXCL16 to reflect different aspects of atherosclerosis-related inflammatory responses, we hypothesized that the combined use of OPG and CXCL16 could provide important prognostic information in ACS patients in relation to both short-term and long-term mortality and that it would add prognostic information to the GRACE risk score. We also examined the ability of OPG and CXCL16 to predict cardiovascular (CV) morbidity and, based on their potential involvement in myocardial remodeling, 17, 18 we focused in particular on the development of HF. Furthermore, we studied whether samples obtained in a stable phase 3 months after the initial event, without the influence of acute myocardial necrosis and reperfusion injury, would provide prognostic information of the same magnitude as that obtained from day 1 samples (obtained within 24 hours of admission). The measurements were made on serum samples obtained from a large series of patients with ACS admitted to a Scandinavian teaching hospital.
Methods

Study Design
The methods in this study and the characteristics of the participants have been described in detail. 19, 20 We used frozen serum samples from Prognosis and Risk in Acute Coronary Syndrome in Sweden (PRACSIS). Patients admitted to the coronary care unit at Sahlgrenska University Hospital, Gothenburg, Sweden, from September 1995 to March 2001, with an ACS, ie, a diagnosis of unstable angina/non-STelevation MI (NSTEMI) or STEMI were eligible. Consecutive patients of both sexes were included to reflect the general ACS population at this center. The main exclusion criteria were age <18 or ≥80 years, noncoronary artery disease associated with an expected life expectancy of <1 year, residence outside the hospital's catchment area, unwillingness, and prior admission resulting in inclusion in the study. The patients included in the current study were those with blood samples available from day 1, and this study group, therefore, comprises 1322 patients. The Regional Ethics Committee approved the study protocol and informed consent was obtained from all individuals.
End Points
Patients were followed up during a median (25th, 75th percentiles) period of 91 (70, 110) months, until January 2007. Survival confirmation and date of death were obtained from the Swedish National Population Registry. Eleven patients, who emigrated from Sweden, were lost to follow-up and censored alive on the day of emigration. In addition to all-cause mortality, CV mortality, the incidence of acute MI and HF, and a composite end point of CV mortality, HF and MI were recorded. The definition of MI was reinfarction during the index hospitalization or readmission for MI with an International Statistical Classification of Disease, Ninth Revision (ICD-9) code 410 or Tenth Revision (ICD-10) code I21 or I22. HF was defined as the development of HF symptoms, Killip class >1, during the index hospitalization or rehospitalization with a primary ICD-9 code 428 or ICD-10 code I50. Readmission diagnoses were obtained from the Swedish Hospital Discharge Registry. Information on cause of death was obtained from the Swedish National Cause of Death Register, and CV mortality was defined as ICD-9 codes 390-459 or ICD-10 codes I00-I99.
Echocardiography
An experienced investigator performed an echocardiographic investigation within 5 days of hospital admission. The biplane left ventricular ejection fraction (LVEF) was calculated by the disc sum method, and tracings were checked for accuracy in the motion mode. 20, 21 
Blood Sampling Procedures
Peripheral venous blood was obtained within 24 hours of admission and at an outpatient visit 90 days after the index admission, by direct venipuncture of an antecubital vein after the patients had been resting for at least 30 minutes. Blood samples were drawn into pyrogen-free tubes without any additives (serum) or with EDTA as the anticoagulant (plasma), stored at room temperature (serum) or immediately immersed in ice water (plasma) for 1 hour before being centrifuged at room temperature (serum) or at +4°C (plasma). All plasma and serum samples were stored at −70°C and thawed at time of serum analysis or once prior to analysis of plasma.
Biochemical Analyses
Serum OPG, CXCL16, and CRP were quantified by an enzyme immunoassay using commercially available matched antibodies (R&D Systems, Minneapolis, MN), as described previously in detail. 7, 8 The intraobserver coefficients of variation were 3.6% for OPG and 3.3% for CXCL16. Troponin T and creatinine kinase MB fractions in serum were measured on a modular platform (Roche Diagnostics, Mannheim, Germany). Pro B-type natriuretic peptide (BNP) 3-108 was measured using immunofluorescent assays calibrated with spiked plasma (Biosite Inc, San Diego, CA). All samples were run in duplicate in a blinded fashion. Total cholesterol concentrations and creatinine in serum were determined by routine laboratory methods, and the glomerular filtration rate was estimated by the Cockcroft-Gault formula. 7
Statistical Analysis
Categorical variables are reported as proportions and continuous variables as median or mean values. Fisher exact and Kruskal-Wallis tests were used to test any difference between the 4 groups in Table 1 , for dichotomous and ordered/continuous variables, respectively. For interaction analysis in the same table, logistic regression or analysis of variance (using logarithmic transformation) was used. Wilcoxon's signed rank test was used for paired testing (ie, difference in markers between time points). Kaplan-Meier plots were produced to visualize cumulative risk during follow-up, and Cox's proportional hazards model was used for other analyses of mortality and morbidity during follow-up, including calculations of hazard ratios with corresponding CIs and interaction analysis. These were performed in all patients for short (90 days) and long (until January 1, 2007) term follow-up. In addition, the latter analysis was also performed in the subgroup of those patients without initial HF. For each end point, analyses of both the upper quartiles of the individual markers as 2 separated variables in the same model were performed, as well as an analysis of the combined variable of the upper quartile in both markers. For each model 3 different adjustments were applied: (1) no adjustment; (2) adjusted for the GRACE risk score (based on age, history of HF, history of MI, heart rate, systolic blood pressure, ST-segment depression on the admission ECG, elevated biomarkers of myocardial necrosis, baseline creatinine levels, and no in-hospital percutaneous coronary intervention), 22 sex, history of diabetes mellitus, and in-hospital medication; and (3) as in (2) but also CRP (log transformed), pro BNP (log transformed), and LVEF (in the subgroup for which all 3 of these variables were available). The fourth quartile (q) of the day 1 measurements from the complete cohort was used to define cut-off values throughout all subgroup analyses. Using logistic regression we assessed the predictive accuracy of the GRACE score, CXCL16 and OPG and CRP and pro BNP, regarding all-cause mortality, using C-statistics based on receiver operating characteristics curves for 69 months of follow-up (the maximum common length of follow-up for all patients) and comparing the areas under the curve using the approach described by DeLong et al. 23 All P values refer to 2-sided tests and were considered statistically significant if <0.05. The authors had full access to and take responsibility for the integrity of the data. All authors have read and agreed to the article as written.
Results
Baseline Characteristics
A total of 1322 patients (30% female, median age 67 years) had OPG and CXCL16 measurements from day one. Of these, Table 1 . The q4 cut-off values were for OPG >4617 pg/mL and for CXCL16 >1706 pg/mL. Those within q4 of both markers, or OPG only, were older and more often presented with STEMI, and higher creatinine kinase MB, troponin T, pro BNP, CRP, Killip class, and GRACE score. They were more frequently treated with thrombolysis and less often with percutaneous coronary intervention and coronary by-pass grafting during the hospital period. Further, they had more often heparin infusion and β blocker treatment, and less often glycoprotein IIb/IIIa inhibitors. The day 1 levels of both CXCL16 and OPG were related (all P<0.0001) to age (r=0.13; r=0.46), indicators of cardiac function in terms of LVEF (r=−0.15; r=−0.25) and pro BNP (r=0.18, r=0.32), marker of myocardial damage in terms of troponin T (r=0.12; r=0.24), as well as of inflammation in terms of CRP (r=0.20; R=0.27). Numerically, all these relationships were lower for CXCL16 than for OPG. CXCL16 was significantly related to OPG (r=0.25; P<0.0001), but there was no significant interaction between CXCL16 and OPG for associations with the different end points in the short-or long-term follow-up. Chemokines depend on glycosaminoglycans (eg, heparin) for the function in vivo, and they have different affinity for specific heparin oligosaccharides, with low affinity across all structures for CXCL16. 24 We found no difference in CXCL16 level with or without heparin infusion (P=0.40) or low molecular weight heparin (P=0.72).
Short-Term Morbidity and Mortality
All deaths during the first 90 days after the index event were attributed to CV mortality. There was a relationship between q4 of CXCL16/OPG either individually (model 1), or both combined (model 2), and the composite end point of CV death, HF and MI ( Table 2) . A strong association was still observed after adjustment for the GRACE score, and in addition in a subgroup (n=727) also after further adjustment for CRP, pro BNP, and LVEF. The inclusion of medications, diabetes mellitus, and sex in these models did not influence the results. High levels of CXCL16 and OPG in combination (model 2) were associated with an increase in CV mortality around 3 times after adjustment for the GRACE score, medication, diabetes mellitus, and sex. The association between q4 of CXCL16/ OPG and HF was of a similar magnitude and remained, in contrast to that for CV mortality, after adjustment for CRP, pro BNP, and LVEF. The q4 of CXCL16/OPG showed no shortterm association with recurrent MI.
Long-Term Morbidity and Mortality
A combination of high CXCL16 and OPG levels was associated with all-cause mortality during long-term follow-up (Table 3) . Although attenuated, these results were still significant after adjustment for the GRACE score. The associations between the 4 combinations of CXCL16 and OPG, in q1-3 or q4, and allcause mortality are shown as Kaplan-Meier curves in Figure 1 , upper panel. The 4 curves were well separated, with the highest mortality in the combined q4 group and the second highest in the q1-3 CXCL16/q4 OPG group. Additionally (Table 3) , q4 CXCL16/q4 OPG was associated with the composite end point of CV death, HF, and MI, and remained so after adjustment for the GRACE score, as well as after adjustment for pro BNP, CRP, and LVEF in the subgroup in which this information was available. Again, the inclusion of medications and diabetes mellitus in these models did not influence the results. Upper quartiles of CXCL16/OPG combined (model 2) was associated with a hazard ratio above 3.0 for long-term CV mortality as well as HF, and although attenuated when adjusted for GRACE score it was still significant, even when considering pro BNP, CRP, and LVEF. Furthermore, individually the upper quartiles of CXCL16 and OPG (model 1) were significant predictors after adjustment. An association with recurrent MI was also present in univariate analysis for q4 CXCL16/OPG combined (model 2), but it was dependent on the CXCL16 component and abolished by adjustment for the GRACE score. 
OPG and CXCL16 Measurements at Different Time Points
To determine the biomarker variation over time after ACS, we measured CXCL16 and OPG levels in serum samples from day 1, day 4, day 90, and day 900, which were available for 155 and 153 patients ( Figure 2 ). Whereas CXCL16 increased during the first days, OPG did not change significantly from day 1 to day 4. However, 90 and 900 days after ACS, concentrations of both markers were lower than at day 1. 
Long-Term Prognosis Without Initial HF
Based on the hypothesis that CXCL16 and OPG would be associated with the long-term prognosis through involvement in the atherosclerotic process, we evaluated patients without prior HF and without HF in relation to the acute event. The results are shown in Table 4 . The composite CXCL16+OPG q4 (model 2) was associated with all-cause mortality, with the combined end point of CV death/HF/MI, as well as with CV mortality, HF, and MI. Having serum levels in the fourth quartile for both markers was associated with triple the risk of CV mortality and more than double the risk of HF or MI. Adjusting for the GRACE risk score, and also in a subgroup for pro BNP, CRP, and LVEF, associations with all end points except MI remained significant. CXCL16 and OPG (model 1) were associated independently of one another with all-cause mortality, the combined end point, CV mortality and with rehospitalization for HF. As illustrated in Figure 1 , lower panel, the lack of high marker values was associated with a low (<10%) incidence of HF. After adjustment for the GRACE score (Table 4) , only CXCL16 levels were independently associated with a higher risk of future morbidity. We found no significant interaction between CXCL16 and OPG for associations with any end point.
Predictive Accuracy of the GRACE Score and Markers
In the entire patient group, the overall prognostic ability of the GRACE score, as expressed by C-statistic, was 0.780 (95% CI, 0.751-0.808) for all-cause mortality. The addition of CXCL16 and OPG increased the C-statistic to 0.797 (95% CI, 0.769-0.825) (P for the difference 0.002). A comparison of the C-statistic for the GRACE score with and without markers among those with complete data revealed that a combination of pro-BNP, CRP, CXCL16, and OPG (C-statistic 0.812; 95% CI, 0.780-0.845) added significantly (P=0.02) to the information provided by the GRACE score alone (0.796; 95% CI, 0.762-0.829) regarding mortality over 69 months. In contrast, adding only CRP and pro-BNP to the GRACE score did not significantly increase prognostic information.
Discussion
The principal finding in the present study is that the combination of OPG and CXCL16 predicts short-and long-term mortality, as well as HF, in a large population of patients with ACS more effectively than information from each marker alone. These associations remained significant after adjustment for the GRACE score. Long-term associations were also significant after adjustment for LVEF, pro BNP, and CRP. Even in subjects without prior HF and with no clinical HF during the hospital phase, the combination of high OPG and high CXCL16 levels was independently associated with A B Figure 1 . Crude Kaplan-Meier curves. A, All-cause mortality up to 10 years after the acute event with various CXCL16 and osteoprotegerin (OPG) levels. B. Only patients without heart failure (HF) before or during the initial acute coronary syndrome event, illustrating rehospitalization for HF up to 10 years in relation to CXCL16 and OPG levels. an increased risk of total and CV mortality and CV morbidity. Finally, the combination of pro-BNP, CRP, CXCL16, and OPG added significantly to the information provided by the GRACE score alone when it came to mortality over 69 months, whereas only adding CRP and pro-BNP did not provide any significant prognostic information. Our findings suggest that the combined measurements of OPG and CXCL16 could provide additional prognostic information beyond that provided by the data from each of these markers, as well as beyond that of traditional risk markers (ie, GRACE score, pro-BNP, and CRP). CV disease is multifactorial involving a wide range of mediators. OPG has been shown to mirror the activity in the OPG/receptor activator of nuclear factor κB ligand/receptor activator of nuclear factor κB system, which is involved in inflammation, matrix remodeling, and calcification in CV disease. 9, 13 In addition, OPG appears also to have chemotactic and matrix-degrading effects on its own. 12 As for CXCL16, it has been shown to mediate T-cell chemotaxis and matrix remodeling, and it also appears to have an effect on the lipid metabolism. 17 In addition, the release of the soluble form of CXCL16 from CXCL16-expressing cells is thought to reflect increased activity in inflammatory pathways which are activated in CV disease, such as those that are induced by interleukin-1β, tumor necrosis factor α, and interferon γ. 25 The ability of the combination of high OPG and high CXCL16 to predict total and CV mortality in ACS patients could reflect that these parameters mirror overlapping, but also distinct, pathways that are involved in atherogenesis and myocardial remodeling.
Myocardial expression and serum levels of OPG are both increased in HF. 26 Elevated circulating OPG levels have been demonstrated in left ventricular pressure overload in patients with aortic stenosis 27 and correlate to left ventricular mass in hypertension, 28 as well as in the general population. 29 Exercise-induced myocardial damage in healthy young men results in increased circulating levels of OPG, which has also been suggested to be involved in muscle repair. 30 The inverse relationship between OPG and LVEF in our material is, therefore, not surprising, and we have also previously 31 noted a relationship between OPG and infarct markers and BNP. Enhanced myocardial expression of CXCL16 has been demonstrated in both experimental and clinical HF, 17 promoting muscle regeneration. 32 Although weaker than for OPG, the relationships we found between CXCL16 and indices of myocardial dysfunction were still significant. There is, therefore, evidence to support a pathophysiological role for both studied markers in the development of HF in our ACS patients. The association between OPG/CXCL16 and HF was further supported by the fact that these markers were able to predict the development of HF even in patients without prior HF and with no clinical signs of HF at admission or during the hospital phase. Both CXCL16 14, 33 and OPG 34 have been implicated in the inflammatory arm of atherogenesis. Based on previous findings relating to the roles of OPG and CXCL16 in the progression of atherosclerosis, 33, 35 we hypothesized that the combination would also be predictive of recurrent MI. In the short term, neither marker was associated with subsequent MI, but, in the long-term, high values of both were related to the development of MI. This was mainly attributed to CXCL16, which remained significant after adjustment for the GRACE score, suggesting that this marker may be more closely related to atherogenesis and plaque destabilization than OPG. In fact, based on its potential to reflect several upstream inflammatory pathways as well as its ability to promote downstream inflammatory and matrix-degrading responses, soluble CXCL16 has been suggested to serve as a reliable marker of progressive atherosclerotic disease. In the present study we found that the ability of CXCL16 to predict short-term CV death/MI/HF was weakened when adjusting for GRACE score, and were not significant when making additional adjustment for pro BNP, CRP, and LVEF. In contrast, CXCL16 was associated with long-term adverse outcome, also after full adjustment. The reasons for this pattern are at present not clear, but it is possible that rather than reflecting the degree of myocardial damage or plaque instability during ACS, which may influence short-term prognosis, increased CXCL16 levels could reflect a state of chronic vascular inflammation and remodeling in these patients predisposing to adverse long-term outcome.
In a recently published study examining its performance in combination with and compared with BNP, the GRACE score appeared to predict not only ACS events but also HF. 36 Some other markers have been shown to add prognostic information to the GRACE score; they include CRP, which modestly improved risk stratification in one study, 37 and BNP which appeared to predict CV events over and beyond the GRACE score. 36 However, in a complicated process like ACS, reflecting enhanced atherogenesis and, in some patients, resulting in maladaptive remodeling with the development of HF, it is unlikely that one particular marker would be able to mirror all the involved pathogenic pathways. To explore the potential benefit of CXCL16 and OPG as prognostic indicators, we therefore adjusted not only for the GRACE score but also for diabetes mellitus, in-hospital medication, pro BNP, LVEF, and CRP. Because the GRACE score typically provides a C-statistic of around 0.8, as was the case in our data, the improvement from adding markers, no matter how well they predict a certain outcome on their own, will appear modest. With the addition of CRP and BNP, no significant change in the areas under the curve was seen, but, adding OPG and CXCL16 to GRACE, CRP, and BNP provided a small yet significant improvement in risk prediction. Together with our other data, showing that the combined measurements of CXCL16 and OPG provide independent information on long-term total mortality, as well as the development of HF, this suggests that these markers may be useful as risk predictors in ACS patients. The fact that the prognostic information was of the same order, no matter whether OPG and CXCL16 were measured in the acute phase or in a later stable phase, further supports their usefulness as biomarkers in ACS.
Strengths and Limitations
The strengths of the present study include the prospective design in a large population of ACS patients, followed up over a long period of time, and the large number of most end points. Repeated measurements of the studied markers over time add valuable information, as does the echocardiographic information on left ventricular function, even though it is available in only a subset of patients. Incomplete laboratory work in some patients and for some of the parameters is a limitation of the present study. The patients were included several years ago, and although a fairly large proportion of our patients were treated according to current treatment guidelines, we have not proved that similar results will be obtained in patients that are treated according to current guidelines. The study population was dominated by men, and although this may represent a confounder, the sex composition in this study reflects the distribution of ACS in the general population. Moreover, although we demonstrate several significant associations between high levels of OPG and CXCL16 and clinical end points, this does not necessarily mean that there is any causal relationship. In addition, the predictive value of CXCL16 and its combination with OPG need to be confirmed in other ACS patient groups.
Conclusions
High levels of both CXCL16 and OPG in ACS appear to be more common with STEMI, with large infarct size and with HF in connection with an acute coronary event. High levels of these markers were able to predict short-term and in particular long-term mortality and morbidity in ACS patients even after adjustment for traditional risk markers. The use of both markers in a multimarker panel appears to be an attractive alternative for risk assessment in ACS, as their pathophysiological roles differ. Our findings also underscore that use of >1 biomarker could be useful in risk stratification of patients with complex CV disorders like ACS.
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